statistiche ricercatore

Continente	#
NA - Nord America	1.806
EU - Europa	736
AS - Asia	677
Continente sconosciuto - Info sul continente non disponibili	155
SA - Sud America	100
AF - Africa	26
OC - Oceania	1
Totale	3.501

Nazione	#
US - Stati Uniti d'America	1.711
SG - Singapore	267
DE - Germania	176
CN - Cina	173
IT - Italia	121
CA - Canada	79
SE - Svezia	78
BR - Brasile	74
UA - Ucraina	74
IE - Irlanda	68
RU - Federazione Russa	64
HK - Hong Kong	62
VN - Vietnam	62
GB - Regno Unito	43
IN - India	27
FR - Francia	26
BD - Bangladesh	19
BE - Belgio	16
FI - Finlandia	16
DK - Danimarca	15
TR - Turchia	14
AR - Argentina	13
IQ - Iraq	11
PK - Pakistan	8
EG - Egitto	7
KR - Corea	7
NL - Olanda	7
PL - Polonia	7
MX - Messico	6
ZA - Sudafrica	6
CO - Colombia	5
PH - Filippine	5
ES - Italia	4
JM - Giamaica	4
RO - Romania	4
TN - Tunisia	4
AT - Austria	3
EC - Ecuador	3
IR - Iran	3
MA - Marocco	3
MY - Malesia	3
VE - Venezuela	3
AE - Emirati Arabi Uniti	2
CI - Costa d'Avorio	2
CL - Cile	2
CR - Costa Rica	2
DO - Repubblica Dominicana	2
EU - Europa	2
LB - Libano	2
LT - Lituania	2
RS - Serbia	2
SA - Arabia Saudita	2
UZ - Uzbekistan	2
AL - Albania	1
AO - Angola	1
BH - Bahrain	1
CH - Svizzera	1
CZ - Repubblica Ceca	1
ET - Etiopia	1
GA - Gabon	1
GR - Grecia	1
HU - Ungheria	1
ID - Indonesia	1
JO - Giordania	1
KG - Kirghizistan	1
KH - Cambogia	1
LU - Lussemburgo	1
MD - Moldavia	1
MZ - Mozambico	1
NO - Norvegia	1
NZ - Nuova Zelanda	1
PR - Porto Rico	1
PS - Palestinian Territory	1
PT - Portogallo	1
SK - Slovacchia (Repubblica Slovacca)	1
SV - El Salvador	1
SY - Repubblica araba siriana	1
TH - Thailandia	1
Totale	3.348

Nome	#
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib	453
Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years	439
Imatinib long term effects study: three years of follow-up and assessment	382
Characterization of compound 584, an Abl kinase inhibitor with lasting effects	381
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells	377
Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy	345
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma	331
Inhibition of RET tyrosine kinase by SU5416	328
In vitro and in vivo activity of SKI-606, a novel Abl/Src inhibitor, against imatinib resistant BCR-ABL plus neoplastic	233
NPM/ALK co-localizes with, and phosphorylates PSF and other RNA-binding proteins	232
Totale	3.501

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	132	0	0	18	8	7	17	7	4	5	18	15	33
2022/2023	325	32	98	37	30	16	39	0	24	14	1	15	19
2023/2024	221	11	10	14	19	28	60	36	9	13	0	2	19
2024/2025	364	19	37	29	30	41	3	30	6	19	45	47	58
2025/2026	981	115	37	91	64	142	48	117	52	98	94	85	38
2026/2027	72	16	45	11	0	0	0	0	0	0	0	0	0
Totale													3.501

Bicocca Open Archive